CSL Behring CSL300_2301 - a 2-part (phase 2b / 3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study.

Clinical Trial Grant

Duke Scholars

Principal Investigator John Paul Middleton Medicine, Nephrology

Administered By

Medicine, Nephrology

Awarded By

CSL Behring LLC

Start Date

June 24, 2025

End Date

January 31, 2030

Administered By

Medicine, Nephrology

Awarded By

CSL Behring LLC

Start Date

June 24, 2025

End Date

January 31, 2030